Mosapride

Mosapride is an orally active gastroenterokinetic compound. Mosapride is a 5HT4 agonist. Mosapride is a CYP inducer. Mosapride has a concentration-dependent inhibitory effect on Kv4.3, and its IC50 value is 15.2 μM. Mosapride can be used in the study of gastrointestinal diseases[1][2][3][4][5][6][7].

Product Specifications

CAS Number

[112885-41-3]

Product Name Alternative

TAK-370; AS-4370

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H332, H335

Target

5-HT Receptor; Cytochrome P450; Potassium Channel

Type

Reference compound

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/mosapride.html

Purity

99.87

Solubility

DMSO : 66.67 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NCC1CN(CC2=CC=C(F)C=C2)CCO1)C3=CC(Cl)=C(N)C=C3OCC

Molecular Formula

C21H25ClFN3O3

Molecular Weight

421.89

Precautions

H302, H315, H319, H332, H335

References & Citations

[1]Tack J, et al. Systematic review: cardiovascular safety profile of 5-HT (4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012 Apr;35 (7) :745-67.|[2]Curran MP, et al. Mosapride in gastrointestinal disorders. Drugs. 2008;68 (7) :981-91.|[3]Kim HS, et al. The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro. Neurogastroenterol Motil. 2008 Feb;20 (2) :169-76.|[4]Kim YH, et al. Measurement of Human Cytochrome P450 Enzyme Induction Based on Mesalazine and Mosapride Citrate Treatments Using a Luminescent Assay. Biomol Ther (Seoul) . 2015 Sep;23 (5) :486-92.|[5]Uchida M, et al. Dual role of mosapride citrate hydrate on the gastric emptying evaluated by the breath test in conscious rats. J Pharmacol Sci. 2013;121 (4) :282-7.|[6]Fujisawa M, et al. The 5-HT4 receptor agonist mosapride attenuates NSAID-induced gastric mucosal damage. J Gastroenterol. 2010 Feb;45 (2) :179-86.|[7]Sung KW, et al. Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2013 Oct;386 (10) :905-16.